Session Reserved for Labcorp
Time: 3:15 pm
day: Day One
Details:
- Cloudman S91 and YUMM1.7 melanoma models were evaluated following treatment with anti-mPD-1 and radiation therapy (RT) using flow cytometry and the NanoString® nCounter PanCancer IO 360™ panel
- Cloudman S91 tumor growth was sensitive to checkpoint inhibition but not RT, while TUMM1.7 tumors responded only to RT
- Treatment-induced immunophenotypic profiles and signaling pathway signatures were distinct between the two models and reflected the
corresponding tumor growth kinetics, thus providing two unique preclinical tools for drug discovery
